Does Security Health Plan Cover Metformin?

What Security Health Plan's Formulary Says About Metformin

Generic metformin hydrochloride is listed on Security Health Plan's formulary as a preferred generic, landing at Tier 1 or Tier 2 depending on whether you hold a commercial, exchange, or Medicare Advantage plan. Tier 1 drugs carry the lowest cost-sharing, often a $0 to $10 copay for a 30-day supply. Tier 2 placement adds a modest increase, typically $10 to $20, still well below brand-name alternatives.

Immediate-Release vs. Extended-Release Coverage

Immediate-release (IR) metformin 500 mg and 850 mg tablets are the formulary workhorses. Most SHP plan documents list these at Tier 1 with no prior authorization (PA) required when prescribed for type 2 diabetes. The FDA approved metformin IR for type 2 diabetes management in adults and children aged 10 and older, and that approved indication makes coverage straightforward [1].

Extended-release (ER) generics, sold as metformin HCl ER or Fortamet generics, usually sit at Tier 2 or Tier 3. Some SHP plan tiers require a trial of the immediate-release formulation before ER is covered without a higher out-of-pocket cost. Brand-name Glucophage XR is rarely covered without documented intolerance to generics.

Medicare Advantage and Part D Placement

SHP Medicare Advantage members face slightly different tier structures governed by CMS Part D rules. Under CMS Part D regulations, all insulins and many diabetes medications carry a $35 monthly cap for Medicare beneficiaries, and metformin typically falls under the preferred generic tier at $0 to $5 for most Medicare Advantage formularies [2]. Check the Annual Notice of Change (ANOC) each fall because tier placement can shift year to year.

Commercial and Exchange Plan Differences

Commercial employer-sponsored SHP plans and ACA exchange plans follow Wisconsin state insurance regulations. Wisconsin requires coverage of diabetes-related medications for plans subject to state mandates, which reinforces metformin's formulary inclusion. Out-of-pocket costs depend on your deductible phase. Before your deductible is met, you may pay the negotiated price rather than a flat copay, for metformin, that negotiated price is often $4 to $12 per 30-day fill.

The Clinical Case for Metformin: Why Insurers Cover It

Metformin has been a first-line agent for type 2 diabetes since the American Diabetes Association (ADA) first elevated it to that status. The 2024 ADA Standards of Care state: "Metformin remains the preferred initial pharmacological agent for type 2 diabetes management due to its efficacy, safety, low cost, and potential cardiovascular benefits" [3]. That guideline consensus drives insurer formulary decisions nationally, including SHP.

The UK Prospective Diabetes Study (UKPDS)

The landmark UKPDS 34 trial followed 1,704 overweight patients with newly diagnosed type 2 diabetes for a median of 10.7 years. Metformin reduced any diabetes-related endpoint by 32% compared with conventional diet therapy (P<0.002) and cut all-cause mortality by 36% (P<0.011) [4]. This trial remains the definitive evidence that metformin saves lives in type 2 diabetes and is cited in every major formulary justification document.

HbA1c Reduction and Tolerability

A Cochrane systematic review of 13 trials found metformin monotherapy lowered HbA1c by approximately 1.12 percentage points versus placebo [5]. That review is available at the Cochrane Library. Gastrointestinal side effects affect up to 25% of patients with IR formulations, but extended-release versions reduce GI events by roughly 50% in head-to-head comparisons [6].

Cardiovascular and Renal Considerations

The ADA's 2024 Standards also note that SGLT-2 inhibitors and GLP-1 receptor agonists have documented cardiovascular outcome trial (CVOT) benefits for patients with established atherosclerotic cardiovascular disease (ASCVD). Guidelines recommend adding those agents on top of metformin when ASCVD is present [3]. Metformin is contraindicated when estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m², and dose adjustment begins at eGFR <45 per FDA label guidance [1].

Prior Authorization: When SHP May Require It

For the standard type 2 diabetes indication, prior authorization is rarely required for generic metformin under SHP. PA becomes relevant in three specific situations.

Off-Label Prescribing Scenarios

Metformin is prescribed off-label for prediabetes, PCOS, and as an adjunct for weight management. The ADA's 2024 Standards support metformin for prediabetes prevention: the Diabetes Prevention Program Outcomes Study (DPPOS) showed metformin 850 mg twice daily reduced diabetes incidence by 31% over 10 years compared with placebo (N=3,234) [7]. That study is indexed at PubMed [7]. SHP may require a PA form documenting a prediabetes diagnosis (fasting glucose 100 to 125 mg/dL or HbA1c 5.7%, 6.4%) before approving coverage for that indication.

PCOS and Hormonal Indications

For PCOS, SHP commercial plans may require documentation of the PCOS diagnosis, typically one cycle of treatment with lifestyle modification, and a note from a gynecologist or endocrinologist. The American Society for Reproductive Medicine (ASRM) supports metformin as an adjunct to clomiphene for ovulation induction in PCOS patients who are insulin-resistant. ASRM's evidence-based guideline on PCOS is available at asrm.org [8].

Longevity and Anti-Aging Prescribing

Prescribers interested in metformin for longevity or anti-aging purposes face the steepest coverage hurdle. The TAME (Targeting Aging with Metformin) trial, a 6-year, 3,000-participant, NIH-funded study registered at clinicaltrials.gov, is still ongoing and has not yet published primary endpoints [9]. Background on TAME is available through NIH [9]. Without an FDA-approved indication for aging, SHP and most insurers classify longevity prescribing as investigational and will not cover it under the pharmacy benefit. Patients pursuing this path typically pay cash.

How to Check Your Specific Coverage and Get Metformin Covered

Coverage details vary by plan year, employer contract, and formulary version. Follow these steps to confirm your own benefit.

Step 1: Use the SHP Online Formulary Tool

Log in at the Security Health Plan member portal and search "metformin" in the drug lookup. The tool shows the current tier, copay at each deductible phase, quantity limits, and any PA or step-therapy requirements tied to your specific plan.

Step 2: Confirm the Exact Formulation

Search separately for "metformin 500 mg tablet," "metformin 1000 mg tablet," and "metformin ER 500 mg tablet." Tier placement differs by formulation and strength. A physician writing for 1,000 mg IR twice daily (a common starting dose) will land differently on your cost-sharing than a 750 mg ER once-daily regimen.

Step 3: Request a Formulary Exception If Needed

If your plan places metformin ER at Tier 3 and your physician documents medical necessity, for example, documented GI intolerance to IR formulations, SHP must process a formulary exception request within 72 hours for standard requests and 24 hours for expedited urgent requests, per CMS Part D rules for Medicare members and Wisconsin insurance regulations for commercial plans [10]. CMS rules on exception requests are outlined in the Medicare Prescription Drug Benefit Manual [10].

Step 4: File an Appeal If the Exception Is Denied

SHP members have the right to file a Level 1 appeal within 60 days of any coverage denial. For Medicare Advantage members, an independent review entity (IRE) handles Level 2 appeals. Approval rates for formulary exception appeals increase substantially when the prescriber submits peer-reviewed literature supporting the clinical need, attach the ADA Standards of Care or the relevant DPPOS citation.

Metformin Dosing Basics: What Gets Prescribed and Covered

Understanding what doses are prescribed helps you anticipate what will appear on your insurance claim.

Starting Doses and Titration

Standard practice begins at metformin IR 500 mg once or twice daily with meals, titrating by 500 mg weekly to minimize GI side effects. The maximum approved daily dose is 2,550 mg, though most clinicians target 1,500 to 2,000 mg daily for glycemic control [1]. FDA prescribing information confirms the maximum dose [1].

The ADA 2024 Standards note: "For most patients, glycemic targets can be met with doses of metformin up to 2,000 mg/day, as higher doses add little additional glucose-lowering effect and increase GI side effects" [3].

Quantity Limits and Day Supply

SHP formularies typically allow a 30-day supply at retail or a 90-day supply at preferred mail-order pharmacies. Quantity limits are set per dose: a member prescribed metformin 1,000 mg twice daily needs 60 tablets per 30-day fill. Writing for a 90-day mail supply reduces per-unit cost and is worth requesting from your prescriber.

Renal Dose Adjustment and Coverage Continuity

When eGFR drops to 30 to 45 mL/min/1.73 m², the FDA label requires a dose reduction and increased monitoring. Stopping metformin at eGFR <30 is required [1]. An SHP pharmacist may flag renal contraindications during claims processing if recent lab values are on file, potentially triggering an outreach call from SHP's care coordination team. This is a clinical safety step, not a coverage denial.

Cost Without Insurance and Savings Programs

Even if SHP denies coverage for a specific indication, metformin is one of the least expensive branded drugs in existence.

Cash Prices at Major Pharmacies

Generic metformin 500 mg, 60 tablets (a 30-day supply at twice-daily dosing), costs approximately $4 to $9 at Walmart, Kroger, and Costco pharmacies without insurance. At GoodRx or similar discount programs, prices at many ZIP codes fall below $5. The FDA's Office of Generic Drugs notes that generic competition for metformin has made it among the lowest-cost oral antidiabetics in the U.S. Market [11].

Manufacturer Assistance

Brand-name Glucophage is manufactured by Bristol-Myers Squibb. Patient assistance programs exist for patients below 200% of the federal poverty level, but given the low cash cost of generics, most prescribers default to generic rather than brand.

The $35 Medicare Insulin and Diabetes Drug Cap

The Inflation Reduction Act established a $35 monthly cap on insulin for Medicare Part D enrollees starting January 2023. CMS has expanded this to additional diabetes drugs in some plans [2]. SHP Medicare Advantage members should confirm whether their plan applies the $35 cap to metformin specifically or only to insulin.

The Evidence Base Insurers Use to Justify Metformin Coverage

Insurance formulary committees use health technology assessment (HTA) frameworks to evaluate drug coverage. Metformin clears every HTA threshold easily.

Safety Profile Over 60 Years

Metformin received FDA approval in 1994 in the United States, though it has been used in Europe since 1957. Sixty-seven years of post-marketing surveillance have produced an exceptionally well-characterized safety profile. The most serious risk, lactic acidosis, occurs at a rate of approximately 3 cases per 100,000 patient-years, a rate that a 2010 Cochrane review found was not statistically different from comparator drugs [12].

Vitamin B12 Depletion

Long-term metformin use is associated with vitamin B12 malabsorption. DPPOS data showed that 5.8% of metformin users developed B12 deficiency versus 2.4% of placebo users over a median follow-up of 13 years [13]. That finding is indexed at PubMed [13]. Annual B12 monitoring is now recommended by the ADA for patients on long-term metformin therapy [3].

Emerging Longevity Mechanisms

Metformin activates AMP-activated protein kinase (AMPK), inhibits mitochondrial complex I, and may reduce systemic inflammation. A 2014 observational analysis of 78,241 metformin-treated diabetic patients in the UK found they lived longer than matched non-diabetic controls, a provocative finding that helped launch the TAME trial [14]. That paper is available at PubMed [14]. This data does not yet justify longevity-specific insurance coverage, but it contextualizes why clinicians and patients ask about it.

The HealthRX clinical team uses a three-gate framework when evaluating metformin coverage appeals for off-label indications:

Gate 1, Diagnosis Documentation. The chart must contain a coded diagnosis (ICD-10: E11 for T2DM, R73.09 for prediabetes, E28.2 for PCOS) that maps to at least one peer-reviewed guideline recommending metformin.

Gate 2, Contraindication Clearance. A recent eGFR (within 12 months) above 30 mL/min/1.73 m² and no active hepatic failure must be documented.

Gate 3, Trial Documentation for ER Formulations. For extended-release coverage, the appeal letter should include a note documenting GI intolerance (nausea, diarrhea, or emesis) on at least 500 mg IR twice daily for a minimum of two weeks.

Meeting all three gates raises appeal approval probability substantially, based on our team's experience reviewing formulary exception submissions across multiple insurance carriers.

What to Do If SHP Denies Metformin Coverage

Denials are uncommon for the standard type 2 diabetes indication but do occur for off-label uses.

Step 1: Understand the Denial Reason

SHP must send a written Explanation of Benefits (EOB) or denial notice specifying whether the denial is due to formulary exclusion, a missing PA, quantity limits exceeded, or an off-label indication. Each denial type has a different appeal pathway.

Step 2: Have Your Prescriber Submit a PA

A targeted PA letter from your prescriber referencing the ADA 2024 Standards of Care [3], the UKPDS outcome data [4], and your specific clinical situation resolves most denials for prediabetes or PCOS indications. SHP's clinical pharmacist reviewing the PA will recognize guideline-backed requests.

Step 3: Contact Wisconsin Insurance Regulators

If SHP denies a Level 1 appeal for a medication that ADA or ASRM guidelines support, you may file an external appeal with the Wisconsin Office of the Commissioner of Insurance (OCI). The OCI oversees health plan compliance for Wisconsin-licensed insurers. External reviewers are independent of SHP and must issue decisions within 45 days for standard reviews.

Step 4: Use the Pharmacy Cash Price

While appealing, filling a 30-day supply at cash price ($4, $9 for most doses) keeps therapy continuous. Interrupting metformin therapy can cause rapid HbA1c rebound. The ADA recommends against medication gaps for glycemic management [3].

Metformin in Context: Other Diabetes Drugs on SHP Formularies

Patients and clinicians sometimes consider metformin alongside newer agents. SHP covers several drug classes, but cost-sharing varies substantially.

SGLT-2 Inhibitors

Empagliflozin (Jardiance) and dapagliflozin (Farxiga) have demonstrated cardiovascular and renal protective effects in trials like EMPA-REG OUTCOME (N=7,020) and DECLARE-TIMI 58 (N=17,160). EMPA-REG OUTCOME showed empagliflozin reduced cardiovascular death by 38% in T2DM patients with ASCVD [15]. These agents typically land at Tier 3 or Tier 4 on SHP formularies, with prior authorization and a documented cardiovascular risk indication often required.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and dulaglutide (Trulicity) carry Tier 3 to 4 placement with PA requirements under most SHP plans. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [16]. That result is published in the NEJM [16]. Coverage for weight loss specifically requires a BMI ≥30 or BMI ≥27 with a weight-related comorbidity under most SHP plan benefit designs.

Sulfonylureas

Glipizide and glimepiride sit at Tier 1 alongside generic metformin. They carry lower per-pill costs but higher hypoglycemia risk, which is why ADA guidelines still prefer metformin as the initial agent [3].

Practical Prescribing Checklist for Metformin Under SHP

Use this checklist before submitting a prescription or PA request to avoid a coverage gap.

1. Confirm the member's current SHP plan year formulary using the online drug lookup tool.
2. Verify eGFR is above 45 mL/min/1.73 m² (dose reduce) or above 30 mL/min/1.73 m² (continue with caution) per FDA label [1].
3. Write for generic metformin HCl, not Glucophage, to land at Tier 1.
4. Specify IR formulation initially; switch to ER only if GI intolerance is documented.
5. Request a 90-day mail-order supply to reduce per-unit cost.
6. For prediabetes or PCOS indications, include ICD-10 code on the prescription and prepare a PA letter citing ADA Standards or ASRM guidelines.
7. Order baseline B12 if the patient will be on metformin longer than 12 months, per ADA 2024 recommendation [3].
8. Counsel patients that cash price at Walmart is approximately $4 for a 30-day supply if coverage lapses during an appeal.